Drug Trial Radar · NCT07158411
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Nov 20, 2025
Primary completion
Jan 30, 2026
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.
Conditions
- Healthy Participants
Interventions
VimseltinibDrug
Administered orally
MetforminDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK): Maximum Observed Plasma Drug Concentration (Cmax) of MetforminTime frame: Predose up to 48 hours postdose
- PK: Area Under the Concentration Versus Time Curve (AUC) of MetforminTime frame: Predose up to 48 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dr. Vince Clinical Research
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.